Hydrogels comprising cell adhesive peptides and methods of use thereof
US-2024376438-A1 · Nov 14, 2024 · US
Cancer examination method and examination kit
US2016103121A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2016103121-A1 |
| Application number | US-201414763481-A |
| Country | US |
| Kind code | A1 |
| Filing date | Feb 13, 2014 |
| Priority date | Feb 13, 2013 |
| Publication date | Apr 14, 2016 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
An object of the present invention is to elucidate a molecular mechanism of ligand-independent activation of EphA2 in cancer cells, make EphA2 a more useful target in the treatment of cancer, and provide a cancer testing method and the like using the mechanism. The present invention provides, for example, a cancer testing method including a step of measuring an amount of an EphA2 protein fragment having a molecular weight of from 30 kDa to 80 kDa in a sample derived from a subject.
First claim
Opening claim text (preview).
1 . A method of testing cancer, comprising a step of measuring an amount of a fragment of EphA2 protein having a molecular weight of from 30 kDa to 80 kDa in a sample derived from a subject. 2 . The method according to claim 1 , wherein the fragment of EphA2 protein is a fragment comprising an N terminal of EphA2 protein. 3 . The method according to claim 1 , wherein the fragment of EphA2 protein is at least one of the following peptides (i) to (iii)…
Assignees
Inventors
Classifications
Physics · mapped topic
- G01N33/5011Primary
Physics · mapped topic
Physics · mapped topic
Physics · mapped topic
Chemistry & Metallurgy · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2016103121A1 cover?
- An object of the present invention is to elucidate a molecular mechanism of ligand-independent activation of EphA2 in cancer cells, make EphA2 a more useful target in the treatment of cancer, and provide a cancer testing method and the like using the mechanism. The present invention provides, for example, a cancer testing method including a step of measuring an amount of an EphA2 protein fragme…
- Who is the assignee on this patent?
- Univ Tokyo
- What technology area does this patent fall under?
- Primary CPC classification G01N33/5011. Mapped technology areas include Physics.
- When was this patent published?
- Publication date Thu Apr 14 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).